IRF8 and B-cell non-Hodgkin lymphoma: We concluded that in B cell lymphoma models, IRF8 KO and/or expression of mutant variants decrease CD74 and HLA-DM expression, mainly deregulating intracellular antigen processing and loading, rather than MHCII expression on the cell surface.